Long-term efficacy of anagliptin in patients with type 2 diabetes mellitus

Long-term efficacy of anagliptin in patients with type 2 diabetes mellitus - Long-term efficacy of anagliptin in patients with type 2 diabetes mellitus

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000048203

Enrollment

380

Registered

2022-06-30

Start date

2022-06-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Outpatients with type 2 diabetes 2.Patients aged 20 years or older on the date of anagliptin administration start 3.Patients who received anagliptin

Exclusion criteria

Exclusion criteria: 1.Type 1 diabetes 2.Patients in the study is judged by the investigator or sub-investigator as inappropriate for any other reason

Design outcomes

Primary

Measure	Time frame
Change in HbA1c level 5 years after administration of anagliptin in patients with type 2 diabetes.	—

Secondary

Measure	Time frame
Changes in the following parameters and markers after administration of anagliptin 1. Metabolic parameters; HbA1c, GA, weight, BMI 2. Liver enzyme markers; AST, ALT, gamma GTP 3. Liver fibrosis markers; Fib-4 index 4. Renal function markers; eGFR, eGFR slope, urinary albumin-creatinine ratio (UACR) 5. Arterial stiffness markers; IMT (mean, maximum), baPWV, API 6. Hemodynamic markers; systolic and diastolic blood pressure, heart rate 7. Lipid markers; total cholesterol, LDL-C, HDL-C, TG 8. Hypoglycaemic markers; subjective hypoglycemia, unawareness hypoglycemia (SMBG)	—

Measure

Time frame

Changes in the following parameters and markers after administration of anagliptin 1. Metabolic parameters; HbA1c, GA, weight, BMI 2. Liver enzyme markers; AST, ALT, gamma GTP 3. Liver fibrosis markers; Fib-4 index 4. Renal function markers; eGFR, eGFR slope, urinary albumin-creatinine ratio (UACR) 5. Arterial stiffness markers; IMT (mean, maximum), baPWV, API 6. Hemodynamic markers; systolic and diastolic blood pressure, heart rate 7. Lipid markers; total cholesterol, LDL-C, HDL-C, TG 8. Hypoglycaemic markers; subjective hypoglycemia, unawareness hypoglycemia (SMBG)

—

Countries

Japan

Contacts

Public ContactKensuke Ofuchi

Naka Kinen Clinic Department of clinical research laboratory

t-osonoi@kensei-kai.com029-353-2800

Outcome results